Efficacy and Mechanism of Osimertinib Combined with Bevacizumab in the Treatment of Postoperative EGFR Positive Stage II-IIIA Lung Adenocarcinoma

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2022 Feb 17

PMID 35173881

Authors

Jian Bao

Zhengsheng Wu

Congjun Zhang

Mingjun Zhang

Yi Wang

Hongxia Li

Xiang Sun

Junfeng Gao

Lei Ge

Yuzhi Li

Hao Wang

Qianying Guo

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the efficacy and mechanism of osimertinib combined with bevacizumab in treating postoperative epidermal growth factor receptor (EGFR) positive stage II-IIIA lung adenocarcinoma.

Methods: In this retrospective study, one hundred and thirty patients with postoperative EGFR positive stage II-IIIA lung adenocarcinoma were divided into two groups according to different treatment methods. Patients treated with osimertinib alone were included in the single group (65 patients). Patients treated with bevacizumab on the basis of the single group were included in the joint group (65 patients). The short-term efficacy, side effects and survival results of the two groups were counted. The changes of serum vascular endothelial growth factor, serum tumor markers and life quality before and after the treatment were observed.

Results: The ORR (66.15%) and DCR (86.15%) in the joint group were significantly higher than those in the single group (47.69% and 70.77%) (both P<0.05). The serum levels of VEGFA, VEGFB, VEGFC, BFGF, HDGF, SDF-1, CEA, CA153, CYFRA21-1 and CA199 in the joint group were lower than those in the single group after the treatment (all P<0.05). No significant difference was shown in the incidence of adverse reactions such as rash, diarrhea, constipation, albuminuria, hypertension and interstitial pneumonia between the joint group and the single group (all P>0.05). After the treatment, the ZPS score of the joint group was lower than that of the single group, and the KPS score was higher than that of the single group (both P<0.05). There was no significant difference in the two-year median DFS and the one or two-year DFS rate between the joint group and the single group (all P>0.05).

Conclusion: Osimertinib combined with bevacizumab in the treatment of postoperative EGFR positive stage II-IIIA lung adenocarcinoma has evident short-term efficacy and mild side effects, which is helpful in improving the disease control rate and life quality. The mechanism may be related to the regulation of serum CEA, CA153, CYFRA21-1, CA199 levels and inhibition of VEGFA, VEGFB, VEGFC, BFGF, HDGF, and SDF-1 levels.

Citing Articles

Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.

Zhou G, Guo L, Xu J, Tang K, Chen J Ther Adv Med Oncol. 2024; 16:17588359241227677.

PMID: 38304850 PMC: 10832416. DOI: 10.1177/17588359241227677.

Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine.

Jiang H, Bu L Front Med (Lausanne). 2024; 10:1323344.

PMID: 38259856 PMC: 10802683. DOI: 10.3389/fmed.2023.1323344.

Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib.

Kaira K, Imai H, Mouri A, Hashimoto K, Miura Y, Shiono A Thorac Cancer. 2023; 14(29):2950-2961.

PMID: 37605832 PMC: 10569903. DOI: 10.1111/1759-7714.15082.

References

Sacdalan D, Mendoza M, Vergara J, Catedral L, Ting F, Leones L . Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma. Med Oncol. 2020; 37(11):106. DOI: 10.1007/s12032-020-01432-3. View

Tumbrink H, Heimsoeth A, Sos M . The next tier of EGFR resistance mutations in lung cancer. Oncogene. 2020; 40(1):1-11. DOI: 10.1038/s41388-020-01510-w. View

Lu X, Yu L, Zhang Z, Ren X, Smaill J, Ding K . Targeting EGFR and EGFR resistance mutations in NSCLC: Current developments in medicinal chemistry. Med Res Rev. 2018; 38(5):1550-1581. DOI: 10.1002/med.21488. View

Reck M, Shankar G, Lee A, Coleman S, McCleland M, Papadimitrakopoulou V . Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations. Expert Rev Respir Med. 2019; 14(2):125-136. DOI: 10.1080/17476348.2020.1701439. View

Sini V, Cassano A, Corsi D, De Laurentiis M, Gamucci T, Mauri M . Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons. Tumori. 2016; 102(5):472-480. DOI: 10.5301/tj.5000555. View

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y . Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15(11):1236-44. DOI: 10.1016/S1470-2045(14)70381-X. View

Muley T, He Y, Rolny V, Wehnl B, Escherich A, Warth A . Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. Lung Cancer. 2019; 130:194-200. DOI: 10.1016/j.lungcan.2019.02.017. View

Kawachi H, Kunimasa K, Kukita Y, Nakamura H, Honma K, Kawamura T . Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy. 2021; 13(10):799-806. DOI: 10.2217/imt-2020-0311. View

Wu L, Ke L, Zhang Z, Yu J, Meng X . Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. Front Oncol. 2021; 10:602762. PMC: 7775519. DOI: 10.3389/fonc.2020.602762. View

10.

Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C . First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. Front Pharmacol. 2018; 9:441. PMC: 5943532. DOI: 10.3389/fphar.2018.00441. View

11.

Guan Y, Song Z, Li Y, Guo H, Shi J, Zhang X . Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an Fusion. Oncologist. 2019; 24(8):1027-1030. PMC: 6693705. DOI: 10.1634/theoncologist.2018-0732. View

12.

Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T . Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. J Thorac Oncol. 2020; 16(2):205-215. DOI: 10.1016/j.jtho.2020.10.006. View

13.

Ricordel C, Friboulet L, Facchinetti F, Soria J . Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. Ann Oncol. 2018; 29(suppl_1):i28-i37. DOI: 10.1093/annonc/mdx705. View

14.

Janne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S . AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372(18):1689-99. DOI: 10.1056/NEJMoa1411817. View

15.

Singhi E, Horn L, Sequist L, Heymach J, Langer C . Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Am Soc Clin Oncol Educ Book. 2019; 39:e187-e197. DOI: 10.1200/EDBK_237821. View

16.

Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G . Bevacizumab in advanced lung cancer: state of the art. Future Oncol. 2017; 13(28):2515-2535. DOI: 10.2217/fon-2017-0302. View

17.

Suda K, Rivard C, Mitsudomi T, Hirsch F . Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Rev Anticancer Ther. 2017; 17(9):779-786. DOI: 10.1080/14737140.2017.1355243. View

18.

Lamberti G, Andrini E, Sisi M, Rizzo A, Parisi C, Di Federico A . Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Crit Rev Oncol Hematol. 2020; 156:103119. DOI: 10.1016/j.critrevonc.2020.103119. View

19.

Zhang Y, Yuan J, Wang K, Fu X, Han X, Threapleton D . The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016; 7(48):78985-78993. PMC: 5346692. DOI: 10.18632/oncotarget.12587. View

20.

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M . Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019; 121(9):725-737. PMC: 6889286. DOI: 10.1038/s41416-019-0573-8. View